{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-037586","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.099449+00:00","generated_at":"2026-05-26T01:52:03.304135+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Viridian reports positive phase 3 data for veligrotug in TED; cash $717.6M","bullets":["Veligrotug met all primary and secondary endpoints in THRIVE and THRIVE-2 for active and chronic TED.","BLA submission on track for 2H 2025; MAA submission expected 1H 2026.","Cash, equivalents, and investments $717.6M as of Dec 31, 2024, funding operations into 2H 2027.","Net loss $269.9M for 2024 vs $237.7M in 2023; R&D expenses rose to $238.3M.","Appointed Radhika Tripuraneni as CMO, succeeding Thomas Ciulla who transitions to consultant."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-037586","json":"https://secwatch.observer/filing/0001193125-25-037586.json","markdown":"https://secwatch.observer/filing/0001193125-25-037586.md","text":"https://secwatch.observer/filing/0001193125-25-037586.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525037586/0001193125-25-037586-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525037586/d865236d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T01:52:03.304135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}